Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity

Inhibitors that block the programmed cell death-1 (PD-1) pathway can potentiate endogenous antitumor immunity and have markedly improved cancer survival rates across a broad range of indications. However, these treatments work for only a minority of patients. The efficacy of anti-PD-1 inhibitors may...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Shanling, Sckisel, Gail, Sahoo, Anupama, Lalani, Almin, Otter, Doug Den, Pearson, Josh, DeVoss, Jason, Cheng, Jay, Casey, Stephanie C., Case, Ryan, Yang, Melissa, Low, Ray, Daris, Mark, Fan, Bin, Agrawal, Neeraj J., Ali, Khaled
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225340/
https://www.ncbi.nlm.nih.gov/pubmed/32457754
http://dx.doi.org/10.3389/fimmu.2020.00832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225340/
https://www.ncbi.nlm.nih.gov/pubmed/32457754
http://dx.doi.org/10.3389/fimmu.2020.00832

Ejemplares similares